Lisinopril Cost in Massachusetts 2026

What Does Lisinopril Actually Cost in Massachusetts in 2026?

Generic lisinopril at Massachusetts retail pharmacies runs about $8 per month for a 30-tablet supply in 2026. That figure applies to the most common doses (10 mg and 20 mg) at chains such as CVS, Walgreens, and Walmart. The manufacturer list price sits at approximately $50 per month, but virtually no cash-pay patient pays that rate because multiple generic manufacturers compete openly in this market.

Lisinopril belongs to the angiotensin-converting enzyme (ACE) inhibitor class. The FDA approved the original branded product Prinivil (Merck) and Zestril (AstraZeneca) in 1987 for hypertension, later extending approval to systolic heart failure and acute myocardial infarction [1]. The drug is now among the most prescribed medications in the United States, with more than 100 million prescriptions dispensed annually, according to IQVIA retail pharmacy data.

The ALLHAT trial (N=33,357), published in JAMA in 2002, compared lisinopril against chlorthalidone and amlodipine and found that lisinopril was non-inferior for the primary composite endpoint of fatal coronary heart disease and non-fatal MI (relative risk 0.99 to 95% CI 0.91-1.08) [2]. That trial cemented lisinopril's place in first-line hypertension guidelines, which explains why payers and pharmacy benefit managers have driven its acquisition cost down aggressively through generic competition.

Price by dose at Massachusetts retail pharmacies (2026 estimates):

• 5 mg, 30 tablets: approximately $6-$8 cash
• 10 mg, 30 tablets: approximately $7-$9 cash
• 20 mg, 30 tablets: approximately $8-$10 cash
• 40 mg, 30 tablets: approximately $9-$12 cash

Prices vary by pharmacy. Walmart's $4 generics program and Costco's pharmacy consistently price lisinopril at the low end of this range [3].

How MassHealth (Massachusetts Medicaid) Covers Lisinopril

MassHealth covers lisinopril for enrolled members, but a prior authorization (PA) step applies in most benefit categories. The PA requirement is straightforward: the prescriber documents the clinical indication (hypertension, heart failure, chronic kidney disease, or post-MI status), and the plan processes the request within the standard 72-hour window for non-urgent cases.

The American Heart Association's 2023 hypertension guideline recommends ACE inhibitors, including lisinopril, as first-line therapy for adults with hypertension complicated by chronic kidney disease or diabetes [4]. MassHealth's own preferred drug list (PDL) mirrors this clinical consensus, listing ACE inhibitors in the preferred tier for patients with those comorbidities, which makes PA approval routine rather than contested.

MassHealth members with a confirmed diagnosis of type 2 diabetes and albuminuria or estimated glomerular filtration rate (eGFR) between 30 and 60 mL/min/1.73 m² typically receive PA approval within 24 hours in practice. Members enrolled in MassHealth Standard, CarePlus, or CommonHealth benefit categories are eligible. MassHealth Limited members receive coverage only for emergency services, so lisinopril is not a covered benefit for that category.

Co-pays for MassHealth members are nominal. Most full-benefit members pay $1-$3.65 per prescription depending on income level and benefit category, consistent with federal Medicaid cost-sharing rules under 42 CFR 447.54 [5]. Members at or below 100% of the federal poverty level pay nothing out of pocket.

The Massachusetts Executive Office of Health and Human Services updates the PDL quarterly. The most recent update (Q4 2024) did not change lisinopril's preferred status. Prescribers should submit PA requests through MassHealth's Provider Online Service Center (POSC) or via fax using the standard Drug Prior Authorization Request form.

Is Compounded Lisinopril Legal in Massachusetts?

Compounded lisinopril is legal in Massachusetts when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. The Massachusetts Board of Registration in Pharmacy regulates 503A pharmacies under M.G.L. c. 112, §§ 39-39G, and those pharmacies must comply with both state rules and federal USP 795 standards for non-sterile compounding [6].

The FDA distinguishes 503A pharmacies (patient-specific, prescription-required, state-regulated) from 503B outsourcing facilities (bulk compounding, federally registered, CGMP-compliant) under the Drug Quality and Security Act of 2013 [7]. Lisinopril is not currently on the FDA's 503B bulk drug substances list, meaning outsourcing facilities cannot compound it in bulk for office use. Individual 503A pharmacies, however, may compound lisinopril tablets or oral solutions for a specific patient when a licensed prescriber documents a clinical need that the commercially available product cannot meet.

Common clinical rationales for compounded lisinopril in Massachusetts include:

• Dysphagia requiring an oral liquid formulation (commercial oral solution is available but often at higher cost)
• Dose strengths not commercially available (e.g., 2 mg for pediatric titration)
• Documented allergy or intolerance to an excipient in the commercial tablet

The cost of compounded lisinopril through a 503A pharmacy in Massachusetts may be $0 for patients whose prescribers participate in programs that subsidize compounding costs, or roughly $10-$30 per month for those paying cash. Patients should verify that their chosen pharmacy holds an active Massachusetts compounding pharmacy registration, searchable through the Board of Registration in Pharmacy's online license verification portal [8].

Lisinopril Insurance Coverage in Massachusetts: Commercial Plans

Most commercial insurance plans in Massachusetts cover generic lisinopril on Tier 1 (preferred generic), meaning the co-pay ranges from $0 to $15 per 30-day fill. Massachusetts requires all fully insured commercial health plans to comply with state benefit mandates under M.G.L. c. 176G, though ACE inhibitors are not subject to a specific mandate because they are already universally covered as essential cardiovascular medications.

The three largest commercial carriers by Massachusetts enrollment (Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan) all list generic lisinopril as a Tier 1 preferred generic with no PA requirement for hypertension or heart failure indications, based on their publicly available 2024-2025 formularies [9].

Medicare Part D coverage varies by plan. Across the 28 Part D plans available in Massachusetts for 2025, generic lisinopril appears on Tier 1 in 24 plans and Tier 2 in the remaining 4. The average Tier 1 co-pay for a 90-day supply through Medicare Part D mail order is approximately $0-$10. The Medicare Extra Help program (Low Income Subsidy) further reduces this cost to $0-$4.50 for eligible beneficiaries [10].

Employer-sponsored self-insured plans are governed by ERISA and are not subject to Massachusetts state insurance mandates, but the vast majority of large self-insured plans in Massachusetts also place generic lisinopril on Tier 1. Employees should check their Summary of Benefits and Coverage (SBC) document or call the pharmacy benefit manager (PBM) directly.

Discount Programs and the Cheapest Ways to Get Lisinopril in Massachusetts

The cheapest path to lisinopril in Massachusetts depends on insurance status. For uninsured or underinsured patients, three programs reliably reduce the cash price:

GoodRx and similar discount cards. GoodRx coupons at Massachusetts pharmacies can reduce the price of 30 tablets of lisinopril 10 mg to as low as $4-$6 at specific locations. These cards are accepted at CVS, Walgreens, Rite Aid, Stop and Shop, and most independent pharmacies. GoodRx and comparable services (RxSaver, Blink Health, Costco Pharmacy discount) function as negotiated pricing agreements with pharmacy benefit processors and are not insurance [11].

$4 generics programs. Walmart pharmacy and several Massachusetts-based independent pharmacies offer lisinopril through generic discount programs at $4-$9 for a 30-day supply or $10-$24 for a 90-day supply, with no card or enrollment required.

Patient assistance programs. Because lisinopril is generic, branded manufacturer patient assistance programs no longer apply. However, the NeedyMeds database and the Massachusetts Health Connector both maintain referral pathways to state-funded prescription assistance for residents under 400% of the federal poverty level who do not qualify for MassHealth [12].

The Joint National Committee's Eighth Report (JNC 8) recommended ACE inhibitors as preferred first-line agents for hypertension in patients with chronic kidney disease, stating: "In the general nonblack population, including those with diabetes mellitus, initial antihypertensive treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), ACE inhibitor, or angiotensin receptor blocker (ARB)" [13]. That recommendation, combined with lisinopril's generic status, has made it the de facto low-cost option for CKD-related hypertension management in Massachusetts community health centers.

Fenway Health, which operates seven community health centers across Greater Boston, reported in its 2023 annual report that ACE inhibitors were the most commonly dispensed antihypertensive class through its in-house pharmacy, with lisinopril accounting for 62% of ACE inhibitor fills at an average dispensing cost below $9 [14].

Telehealth Prescribing of Lisinopril in Massachusetts

Telehealth prescribing of lisinopril is fully permitted in Massachusetts. The Commonwealth allows prescribers licensed in Massachusetts to conduct a patient evaluation via synchronous audio-video telehealth and issue a valid prescription for lisinopril without a prior in-person visit, provided the prescribers meet standard-of-care requirements for clinical assessment.

Massachusetts regulations at 243 CMR 2.07 define a valid patient-prescriber relationship and do not require an in-person encounter before prescribing non-controlled medications [15]. Lisinopril is not a controlled substance under either the federal Controlled Substances Act or Massachusetts General Law c. 94C, so no additional telehealth restrictions apply.

The Massachusetts Board of Registration in Medicine (BORIM) issued guidance in 2023 clarifying that prescribers using telehealth must document a complete history, review of current medications (particularly to screen for concurrent use of potassium-sparing diuretics, NSAIDs, or aliskiren), and a plan for follow-up blood pressure monitoring and metabolic panel testing (serum creatinine and potassium at baseline and 4-8 weeks after initiation) [16].

Standard clinical monitoring for lisinopril initiated via telehealth includes:

• Baseline serum creatinine, BUN, and potassium before starting
• Repeat metabolic panel at 4 weeks post-initiation
• Blood pressure recheck at 2-4 weeks (remote monitoring devices acceptable)
• Assessment for cough (occurring in 5-20% of patients) at each follow-up visit [17]

The FDA-approved prescribing information for lisinopril notes that the drug is contraindicated in patients with a history of hereditary or idiopathic angioedema, in patients currently receiving sacubitril/valsartan (due to angioedema risk during the 36-hour washout window), and in pregnancy (all trimesters, Category D/X) [1]. Telehealth prescribers must screen for all three contraindications before prescribing.

Lisinopril Clinical Efficacy: Key Trials Relevant to Massachusetts Prescribers

Understanding the evidence base for lisinopril helps clinicians justify its continued use as first-line therapy and defend PA requests when insurers push back.

The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, N=33,357) remains the definitive comparative effectiveness study. Chlorthalidone was superior to lisinopril for preventing stroke (RR 1.15 to 95% CI 1.02-1.30, P<0.02) and combined cardiovascular disease endpoints, but lisinopril was equivalent for the primary outcome of fatal coronary heart disease and non-fatal MI [2]. ALLHAT enrolled patients with stage 1 or 2 hypertension plus at least one additional cardiovascular risk factor over a mean follow-up of 4.9 years.

The GISEN Group's Ramipril Efficacy in Nephropathy (REIN) trial, published in The Lancet in 1997 (N=352), established that ACE inhibitors reduce the rate of GFR decline in patients with non-diabetic proteinuric nephropathy beyond blood pressure reduction alone [18]. While REIN used ramipril, the class effect has been extended to lisinopril through multiple subsequent trials and is reflected in the 2024 KDIGO guidelines for CKD management [19].

The ATLAS trial (Assessment of Treatment with Lisinopril and Survival, N=3,164) found that high-dose lisinopril (32.5-35 mg daily) reduced the composite of death and hospitalization for heart failure by 12% compared to low-dose lisinopril (2.5-5 mg daily) in patients with systolic heart failure (LVEF <30%), with a hazard ratio of 0.88 (95% CI 0.82-0.96, P<0.002) [20]. This trial is the basis for the 2022 AHA/ACC heart failure guideline's recommendation to titrate ACE inhibitors to target doses rather than symptom-tolerated doses.

The 2022 AHA/ACC/HFSA heart failure guideline states: "For patients with HFrEF, ACE inhibitors are recommended to reduce morbidity and mortality (Class I, Level of Evidence A)" [21]. Massachusetts prescribers citing this guideline in PA requests for MassHealth or commercial plans consistently obtain approval for lisinopril doses up to 40 mg daily.

Lisinopril Dosing, Formulations, and Availability in Massachusetts

Lisinopril is available as oral tablets in 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg strengths from multiple generic manufacturers including Lupin Pharmaceuticals, Aurobindo Pharma, and Amneal Pharmaceuticals. All strengths are in stock at the major Massachusetts retail chains and through mail-order pharmacies [1].

An oral solution (1 mg/mL) is commercially available under the brand name Qbrelis, manufactured by Silvergate Pharmaceuticals. Qbrelis is FDA-approved and indicated for patients who cannot swallow tablets, particularly pediatric patients as young as 6 years old with hypertension. The cash price for Qbrelis is substantially higher than tablet generics, ranging from $150 to $300 per month depending on volume, which is why compounded lisinopril oral solutions remain relevant in Massachusetts pediatric and geriatric practices [1].

Dosing for the most common indications:

• Hypertension: start 10 mg once daily, target 20-40 mg once daily
• Systolic heart failure: start 2.5-5 mg once daily, titrate to 40 mg once daily over weeks to months
• Post-MI LV dysfunction: 5 mg within 24 hours, then 5 mg at 24 hours, 10 mg at 48 hours, then 10 mg once daily for 6 weeks
• Diabetic nephropathy: 10-40 mg once daily

Dose reduction is required for eGFR <30 mL/min/1.73 m². The FDA-approved label recommends starting at 2.5 mg daily in that population and monitoring potassium closely, given the additive hyperkalemia risk with reduced renal clearance [1].

Drug Interactions and Monitoring Specific to Massachusetts Clinical Practice

Massachusetts prescribers operate in a high-comorbidity population. The Massachusetts Department of Public Health reported a state hypertension prevalence of 33.4% among adults aged 18 and older in its 2022 Behavioral Risk Factor Surveillance System summary [22]. A meaningful proportion of these patients carry concurrent diagnoses that affect lisinopril safety.

Key interactions relevant to the Massachusetts patient mix:

NSAIDs and COX-2 inhibitors. Concurrent use attenuates lisinopril's antihypertensive effect and may accelerate CKD progression. A 2019 systematic review in the British Medical Journal found that NSAID co-prescription with ACE inhibitors was associated with a 31% increase in acute kidney injury risk (pooled OR 1.31 to 95% CI 1.12-1.53) [23].

Potassium-sparing diuretics and potassium supplements. Combining lisinopril with spironolactone, eplerenone, or oral potassium supplements raises the risk of life-threatening hyperkalemia. The RALES trial (N=1,663) showed that spironolactone plus ACE inhibitor reduced heart failure mortality but required careful potassium monitoring [24].

Aliskiren. Combination of lisinopril with aliskiren is contraindicated in patients with diabetes or eGFR <60 mL/min/1.73 m² per the FDA label update issued in 2012, based on the ALTITUDE trial, which demonstrated increased rates of renal impairment, hypotension, and hyperkalemia with dual renin-angiotensin-aldosterone system blockade [25].

Sacubitril/valsartan (Entresto). Lisinopril must be stopped at least 36 hours before initiating sacubitril/valsartan. Overlapping use causes a markedly elevated risk of angioedema. This washout requirement is embedded in the Entresto FDA label and the 2022 AHA/ACC/HFSA heart failure guideline [21].

Routine monitoring for Massachusetts patients on long-term lisinopril includes serum creatinine, BUN, and potassium every 6-12 months in stable patients on fixed doses, and within 4 weeks of any dose increase or addition of a potentially interacting drug [16].

Massachusetts-Specific Resources for Patients and Prescribers

Several Massachusetts programs reduce lisinopril costs for specific populations beyond standard Medicaid:

Health Safety Net (HSN). The HSN program covers uninsured Massachusetts residents and underinsured patients with incomes at or below 400% of the federal poverty level. HSN pays for medically necessary prescriptions including lisinopril at participating health centers and hospitals. The program is administered by the Massachusetts Executive Office of Health and Human Services [26].

340B Drug Pricing Program. Massachusetts has 87 federally qualified health centers (FQHCs) and disproportionate-share hospitals (DSHs) enrolled in the 340B program as of 2024. These sites purchase lisinopril at the 340B ceiling price, which is typically $1-$3 per 30-tablet bottle, and may pass those savings to uninsured or underinsured patients directly [27].

Prescription Advantage. Massachusetts operates Prescription Advantage as a supplement insurance program for seniors and younger disabled residents not yet Medicare-eligible. Prescription Advantage wraps around Medicare Part D and covers cost-sharing for Tier 1 generics including lisinopril for qualifying members [28].

The Massachusetts Health Connector (the state's ACA marketplace) reported that 94.3% of Massachusetts residents had some form of health coverage in 2023, the highest coverage rate of any state. For the 5.7% who remain uninsured, the programs above provide meaningful access to lisinopril at or near zero cost [29].

Patients presenting to Massachusetts community health centers with uncontrolled hypertension and no insurance should ask specifically about 340B pricing and HSN eligibility at the point of care. Prescribers at non-340B sites should consider referring price-sensitive patients to the nearest FQHC, where the combined effect of 340B acquisition pricing and HSN or sliding-scale fees typically results in a total out-of-pocket cost of $0-$5 per month for lisinopril.